Coya Therapeutics Enrolls 100th Participant In Phase 2/3 ALSTARS Trial Of COYA 302
Benzinga Newsdesk 1 month ago
BiotechGeneralNews
Based on current screening and enrollment rates, topline data anticipated inearly Q2 2027Additional participants continue to roll over into the active extension arm of the trialCOYA 302 has received FDA Fast Track
- Based on current screening and enrollment rates, topline data anticipated inearly Q2 2027
- Additional participants continue to roll over into the active extension arm of the trial
- COYA 302 has received FDA Fast Track designation for the treatment of ALS